Takeda, Japan’s largest pharmaceutical company, has announced plans to buy Swiss rival Nycomed for $13.6 billion (SFr12 billion).This content was published on May 19, 2011 - 10:18
Nycomed, which has its headquarters in Zurich, is a privately-owned company that produces a variety of prescription as well as over the counter products.
“Nycomed gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales,” said Takeda CEO Yasuchika Hasegawa in a statement on Thursday.
Takeda is known for Actos, its diabetes drug. Nycomed’s lung drug roflumilast – known as Daxas in Europe and Daliresp in the United States – is used to treat chronic obstructive pulmonary disease.
The deal would not include Nycomed’s US dermatology unit.
This article was automatically imported from our old content management system. If you see any display errors, please let us know: firstname.lastname@example.org